This product is a human IgG1, κ antibody that can recognize human TNFRSF8.
Figure 1 Anti-Human CD30 Therapeutic Antibody (TAB-153) in ELISA
ELISA analysis of TAB-153 was performed by coating with Recombinant Human CD30 Protein. Then blocked with BSA, and incubated with Anti-Human CD30 Antibody (TAB-153). The HRP-conjugated goat anti-human IgG as a secondary antibody. Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.
Figure 2 Chimeric (mouse/Human) Anti-TNFRSF8 Recombinant Antibody (TAB-153) in ELISA
ELISA analysis of TAB-153 was performed by coating with CD30, Human, Recombinant.
The secondary antibody: HRP-Anti-Human IgG (H+L)
This is a product of Creative Biolabs' Hi-Affi™ recombinant antibody portfolio, which has several benefits including:
• Increased sensitivity
• Confirmed specificity
• High repeatability
• Excellent batch-to-batch consistency
• Sustainable supply
• Animal-free production
See more details about Hi-Affi™ recombinant antibody benefits.
Download resources about recombinant antibody development and antibody engineering to boost your research.
Select a product category from the dropdown menu below to view related products.
CAT | Product Name | Application | Type |
---|---|---|---|
TAB-144 | Anti-Human CD30 Recombinant Antibody (Iratumumab) | ELISA, FC, IP, FuncS, IF, Neut, ICC | IgG1 - kappa |
To accurately reference this product in your publication, please use the following citation information:
(Creative Biolabs Cat# TAB-153, RRID: AB_3111839)
For Research Use Only. Not For Clinical Use.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.